



MARKET RELEASE

2 August 2017

ResApp Health Limited

SUSPENSION FROM OFFICIAL QUOTATION

The securities of ResApp Health Limited (the “Company”) will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to its SMARTCOUGH-C study.

Security Code: RAP

Anjuli Sinniah
SENIOR ADVISER, LISTINGS COMPLIANCE (PERTH)

2 August 2017

Dale Allen
Adviser, Listings Compliance (Perth)
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

Dear Dale

RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION REQUEST

Further to the request on 31 July 2017 for the securities of ResApp Health Limited (“**Company**”) to be placed in trading halt, the Company hereby requests that the securities be placed in voluntary suspension in accordance with ASX Listing Rule 17.2 pending release of an announcement in relation to the Company’s SMARTCOUGH-C study. The Company is in the process of completing clinical data final review prior to the analysis and release of top-line results from this study.

The Company requests that the voluntary suspension end on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by 9 August 2017.

The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension.

Yours faithfully



Nicki Farley
Company Secretary
ResApp Health Limited